The purpose of this study is to determine whether oral famotidine, a histamine type 2 receptor antagonist already widely used with very few side effects in other indications in children, is effective in reducing endothelial expression of P-selectin in children with sickle cell disease (SCD).
This pilot study will constitute the essential prerequisite for a randomized clinical trial comparing the efficacy of famotidine with that of placebo in the prevention of vaso-occlusive crises in SCD patients.
| Slimane ALLALI, MD, PhD | |
| +33-(0)1-44-49-48-96 | |
| [email protected] |
| Prissile BAKOUBOULA, PhD | |
| +33-(0)1-71-19-64-94 | |
| [email protected] |
1 Year - 17 Years
Phase 2/Phase 3
Interventional
All
Drug
child or adolescent aged 1 year to 17 years and 10 months, followed at the Necker-Enfants malades Hospital for a SS or Sβ0 SCD;
having at least one vaso-occlusive crisis in the year prior to inclusion;
for young girl of childbearing age (≥ 15 years old), a negative pregnancy test;
signed informed consent of the 2 parents or legal representative(s) and of the child of expressive age or the adolescent;
beneficiary of social security coverage or entitled (excluding AME)
treatment with crizanlizumab (anti-P-selectin antibody);
treatment with atazanavir/ritonavir in combination with tenofovir;
known hypersensitivity to famotidine or to other histamine type 2 (H2) receptor antagonists;
cardiovascular history such as: arrhythmia, AVB (atrioventricular block), QT prolongation;
renal failure characterized by creatinine clearance <60 mL/min;
hepatic cytolysis (ALT ≥ 3N);
neutropenia (<1 G/L), thrombocytopenia (<80 G/L), reticulopenia (<80 G/L);
predictable poor adherence to treatment;
pregnancy or breastfeeding;
participation in another interventional research involving the human person;
planned bone marrow transplant or gene therapy within one month of inclusion.
Within 3 months prior to inclusion:
red blood cell transfusion;
introduction of hydroxyurea or modification of hydroxyurea doses;
introduction of L-glutamine or modification of L-glutamine doses;
introduction of voxelotor or modification of voxelotor doses;
taking oral or IV corticosteroids or any other immunomodulatory treatment;
taking an antihistamine treatment
In the month preceding inclusion:
occurrence of a vaso-occlusive crisis, acute chest syndrome or any vaso-occlusive phenomenon (acute splenic sequestration, priapism, stroke, occlusion of the central retinal artery, papillary necrosis);
occurrence of fever (≥ 38°C) or any infectious episode, febrile or not, suspected or confirmed, of a viral, bacterial, fungal or parasitic nature ;
occurrence of an acute hemolytic episode (increase in jaundice and pallor, decrease in hemoglobin level of ≥ 1 g/dL compared to baseline hemoglobin, increase in LDH and/or AST and/or free bilirubin deemed significant by the child's referring physician).